ACMT Provides New insights into Sleeping Pills, Drugs of Abuse, and Social Media in Medicine in the June Issue of JMT - May 29, 2013
posted on 1:47 PM, June 25, 2014
Click here for a .pdf of this press release.
PRWeb ebooks - Another online visibility tool from PRWeb
Media in Medicine in the June Issue of the Journal of Medical Toxicology
The Journal of Medical Toxicology, the official journal of the American College of Medical
Toxicology, highlights the dangers of designer drugs, risks of drugs used to treat insomnia, and
the power of social media in medicine in the June issue.
Phoenix, Arizona (PRWEB) May 29, 2013 -- In a report from Minnesota, a wave of bad outcomes associated
with the 2C class of designer drugs is described in “2C or Not 2C: Phenethylamine Designer Drug Review.”
Since many health providers are not familiar with 2C drugs and the drugs are not easily identified using
standard hospital-based toxicology tests, diagnosis of poisoning can be challenging. According to lead author
Be Vang Dean: “Understanding the pharmacology and toxicology of these agents is essential in order to
provide the best medical care for these patients.”
Sameir Alhadi and co-authors from California contribute to the growing body of literature on the synthetic
cannabinoids and their associated complications with the report “High Times, Low Sats: Diffuse Pulmonary
Infiltrates Associated with Chronic Synthetic Cannabinoid Use.” The authors point out that synthetic
cannabinoids have been reported to adversely affect the heart and brain, and caution physicians to be aware of
their significant respiratory effects.
According to lead investigator Alex Manini in the study “Opioid Receptor Polymorphism A118G Associated
with Clinical Severity in a Drug Overdose Population,” an inherited vulnerability might be one explanation for
the recent increase in U.S. mortality from prescription opioids. Using an emergency department cohort
population, they found that a particular genetic mutation is associated with increased vulnerability to overdose
with these drugs.
Naren Gunja, a physician toxicologist from Australia details the adverse events associated with the popular “Zdrugs”
prescribed for insomnia in his article “In the Zzz Zone: The Effects of Z-Drugs on Human Performance
and Driving.” This class of medications includes agents such as zolpidem (Ambien™), zopiclone (Lunesta™),
and zaleplon (Sonata™). In addition to a growing number of cases of amnesia, hallucinations, and suicidality in
users of the “Z-drugs”, Gunja warns prescribers of these agents “the increased risk of falls and motor vehicle
collisions is notably significant for elderly insomniacs.”
Michael Chary and co-authors from New York propose a new model for characterizing new drug use patterns
in an article entitled “Leveraging Social Networks for Toxicovigilance.” The authors suggest popular social
network platforms such as Facebook and Twitter can be powerful tools for clinicians. “Toxicovigilance via
social networks will help prepare frontline clinicians to better recognize the appearance [of new drugs of abuse]
and attend to the needs of their communities.” Chary recognizes the potential benefit of real-time updates in
social media, as “insights from these methods … may be of assistance in tailoring interventions and campaigns
These articles, and many others that advance the science and practice of medical toxicology, can be found in the
June issue of the Journal of Medial Toxicology (JMT), the official journal of the American College of Medical
ACMT is a professional, nonprofit association of physicians with recognized expertise in
medical toxicology. The College is dedicated to advancing the science and practice of medical toxicology
through a variety of activities.